# Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Canonical URL: https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-achondroplasia-at-iccbh-2026-cf687b9b
Ticker: ASND
Company: Ascendis Pharma
Source: Ascendis Pharma
Published: 2026-06-25 20:01 EST
Original Source URL: https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-showcase-advances-treatment-achondroplasia-iccbh-2026
## Summary

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th

## Article Body
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th
## Recent Company News
- 2026-06-30 12:30 EST — [Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial](https://biopharmsignal.com/news/ASND/children-with-achondroplasia-treated-with-transcon-cnp-showed-continued-improvem-93d02f62) — Source: Ascendis Pharma
- 2026-06-26 20:01 EST — [Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®](https://biopharmsignal.com/news/ASND/ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1-d1ad8aa7) — Source: Ascendis Pharma
- 2026-06-25 20:01 EST — [Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026](https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-achondroplasia-at-iccbh-2026-cf687b9b) — Source: Ascendis Pharma
- 2026-06-25 13:46 EST — [Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/phase-3-data-show-transconr-pth-replicated-systemic-actions-of-endogenous-pth-through-week-182-in-adults-with-hypoparathyroidism) — Source: Ascendis Pharma
- 2026-06-25 13:46 EST — [5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/5-year-phase-2-data-show-transconr-pth-replicated-systemic-actions-of-endogenous-pth-in-adults-with-hypoparathyroidism) — Source: Ascendis Pharma
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)